Tranquis Therapeutics Revenue and Competitors
Estimated Revenue & Valuation
- Tranquis Therapeutics's estimated annual revenue is currently $1.7M per year.
- Tranquis Therapeutics's estimated revenue per employee is $155,000
Employee Data
- Tranquis Therapeutics has 11 Employees.
- Tranquis Therapeutics grew their employee count by -15% last year.
Tranquis Therapeutics's People
Name | Title | Email/Phone |
---|---|---|
1 | Sr. VP Technical Operations | Reveal Email/Phone |
2 | SVP, Clinical Evidence Generation | Reveal Email/Phone |
3 | VP Medicinal Chemistry & Drug Discovery | Reveal Email/Phone |
4 | SVP Translational Sciences | Reveal Email/Phone |
5 | Chief Medical Officer | Reveal Email/Phone |
6 | Sr. Manager, Operations | Reveal Email/Phone |
7 | President & CEO | Reveal Email/Phone |
Tranquis Therapeutics Competitors & AlternativesAdd Company
Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
---|---|---|---|---|---|
#1 | $4.4M | 57 | -8% | $53M | N/A |
#2 | $21.2M | 137 | -26% | $110M | N/A |
#3 | $0.9M | 6 | 0% | N/A | N/A |
#4 | $2.3M | 15 | 15% | N/A | N/A |
#5 | $1.6M | 10 | -17% | N/A | N/A |
#6 | $0.7M | 9 | 50% | N/A | N/A |
#7 | $11.5M | 74 | -12% | N/A | N/A |
#8 | $0.4M | 275 | 10% | $236.7M | N/A |
#9 | $4M | 51 | -74% | $160M | N/A |
#10 | $2.3M | 15 | 15% | N/A | N/A |
What Is Tranquis Therapeutics?
Tranquis Therapeutics is discovering and developing innovative medicines with the potential to revolutionize the management of neurodegenerative and aging-related diseases and to dramatically reduce the burden these illnesses place on patients, families and societies worldwide. Founded on ground-breaking neuro-immunology research from the laboratory of Professor Edgar Engleman, MD, at Stanford University, Tranquis' novel therapeutic approach targets underlying myeloid immune cell dysfunction that has been linked to a variety of nervous system disorders. The company's portfolio is comprised of small molecules which cross the blood-brain barrier, and the lead therapeutic candidate has demonstrated highly encouraging effects in challenging preclinical models of Amyotrophic Lateral Sclerosis (ALS), Frontotemporal Dementia (FTD), Parkinson's Disease (PD), and age-related cognitive impairment. Tranquis plans to initiate development in orphan neurodegenerative diseases such as ALS and FTD and later expand into more prevalent diseases such as PD and Alzheimer's Disease. For more information, visit www.tranquis.com.
keywords:N/AN/A
Total Funding
11
Number of Employees
$1.7M
Revenue (est)
-15%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Tranquis Therapeutics News
Tranquis Therapeutics is a breakthrough biopharmaceutical company focused ... MD, at Stanford University, Tranquis' novel therapies work by...
Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
---|---|---|---|---|
#1 | $0.5M | 11 | -21% | $18.6M |
#2 | $3.5M | 11 | -21% | N/A |
#3 | $1.7M | 11 | 0% | N/A |
#4 | $1M | 11 | 0% | N/A |
#5 | $1M | 11 | 10% | N/A |